ReviewFrontiers in cardiovascular medicine2025
Assessing the impact of transcatheter edge-to-edge repair on reverse remodeling in secondary mitral regurgitation: a systematic review and meta-analysis.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Transcatheter edge-to-edge repair (TEER) is a minimally invasive approach to reduce secondary mitral regurgitation (SMR) in patients with heart failure. However, there is limited evidence on its effectiveness in achieving reverse remodeling. Our aim was to assess the effects of TEER over time and to compare the effects of TEER plus GDMT vs. GDMT alone on echocardiographic parameters. Methods: A systematic search of MEDLINE, EMBASE, and CENTRAL was conducted from inception to November 16, 2023. Eligible studies included patients with SMR treated with TEER and echocardiographic follow-ups. We evaluated changes in left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left atrial volume (LAV), left ventricular ejection fraction (LVEF) and NTproBNP levels. Results: Of 9,290 identified studies, 38 met inclusion criteria. After TEER, statistically significant reductions were observed in LVEDD (-1.63 mm), LVESD (-1.20 mm), LVEDV (-14.21 mL), and LVESV (-9.24 mL). Changes in LAV (-5.70 mL) and LVEF (+1.10%) were not statistically or clinically meaningful. NT-proBNP decreased substantially (-1,340 pg/mL). In comparative analyses, TEER plus GDMT did not show statistically significant differences vs. GDMT alone for any parameter, including LVEDD (-1.02 mm), LVEDV (-11.98 mL), LVEF (-0.14%), and LVESV (-5.29 mL). TEER reduced grade 3-4 MR from 99% to 9%. Systematic Review Registration: identifier CRD42023483404. Conclusion: TEER results in statistically significant but clinically small changes in echocardiographic parameters, and no clear advantage over GDMT alone. These findings should be interpreted with caution given the high heterogeneity and low certainty of evidence. Further studies are needed to define which SMR patient subgroups may derive meaningful reverse-remodeling benefit from TEER. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=483404, PROSPERO CRD42023483404.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.